EUVIMEDEUVIMED entdecken
Crossref

Development of Cyclic Peptide‐Based Radiotracers for uPAR

Xingkai Wang, Xu Zhang, Siqi Zhang, Lulu Zhang, Jieting Shen, Yingzi Zhang, Hailong Zhang, Ming-Rong Zhang, Rui Wang, Kuan Hu iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202500061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Xingkai Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Receptors, Urokinase Plasminogen Activator, Peptides, Cyclic, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The urokinase plasminogen activator (uPA) system has garnered attention as a promising biomarker, with the uPA receptor (uPAR) playing a central role in system regulation and demonstrating strong associations with tumorigenicity, invasion, and metastasis. Radioligands targeting uPAR have emerged as powerful tools for the early diagnosis and treatment of malignant tumors. In this study, we developed and evaluated three novel cyclic peptide‐based positron emission tomography (PET) radioligands, denoted as [⁶⁴Cu]CARP‐1, [⁶⁴Cu]CARP‐2, and [⁶⁴Cu]CARP‐3, for uPAR imaging. These radioligands differ in the chiral configuration of their disulfide bond crosslinkers, which influences their binding ability and pharmacokinetic profiles. Among the three, [⁶⁴Cu]CARP‐2 demonstrated optimal tumor radioactivity accumulation, specificity, and favorable pharmacokinetics in an MC38 tumor‐bearing mouse model. Compared to [⁶⁴Cu]DOTA‐AE105, a well‐characterized radiotracer currently under clinical investigation, [⁶⁴Cu]CARP‐2 exhibited reduced non‐specific uptake and rapid clearance from normal tissues. These attributes highlight its potential as a diagnostic tool with improved imaging accuracy. The promising preclinical performance of [⁶⁴Cu]CARP‐2 underscores its potential for further clinical investigation as a uPAR‐targeting radiotracer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Urokinase Plasminogen ActivatorPeptides, CyclicRadiopharmaceuticalsAnimalsMicePositron-Emission TomographyHumansCopper RadioisotopesCell Line, TumorTissue DistributionMice, Inbred BALB C

Stichwörter der Autor:innen

Cyclic peptidePET imagingUrokinase-type plasminogen activator receptor

Substanzen

Receptors, Urokinase Plasminogen ActivatorPeptides, CyclicRadiopharmaceuticalsCopper Radioisotopes

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing, 1000…
  • Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 211166, China.
  • Department of Orthopaedics, the Second Affiliated Hospital of Soochow University, Suzhou, 215031, China.
  • Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Sciences, Lanzhou University, Lanzhou, 730000, China.
  • Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, 263-8555, Japan.

ORCID-Profile: Kuan Hu

Förderung

  • National Natural Science Foundation of China
  • Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences
  • CAMS Innovation Fund for Medical Sciences
  • Beijing Nova Program and Beijing Nova Program Interdisciplinary Cooperation Project
  • Beijing Natural Science Foundation
  • Fundamental Research Funds for the Central Universities
  • CIRP Open Fund of Radiation Protection Laboratories
  • China National Nuclear Corporation Young Talent Program

Zitieren

APA

Wang, X., Zhang, X., Zhang, S., Zhang, L., Shen, J., Zhang, Y., Zhang, H., Zhang, M. R., Wang, R., & Hu, K. (2025). Development of Cyclic Peptide‐Based Radiotracers for uPAR. ChemMedChem. https://doi.org/10.1002/cmdc.202500061

Vancouver

Wang X, Zhang X, Zhang S, Zhang L, Shen J, Zhang Y, et al. Development of Cyclic Peptide‐Based Radiotracers for uPAR. ChemMedChem. 2025. doi:10.1002/cmdc.202500061

BibTeX
@article{Wang2025,
  author = {Wang, Xingkai and Zhang, Xu and Zhang, Siqi and Zhang, Lulu and Shen, Jieting and Zhang, Yingzi and Zhang, Hailong and Zhang, Ming-Rong and Wang, Rui and Hu, Kuan},
  title = {Development of Cyclic Peptide‐Based Radiotracers for uPAR},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202500061}
}
Kostenlos starten →